To Evaluate the Pharmacokinetics and Safety of Yimitasvir Phosphate Capsules in Subjects With Moderate and Severe Liver Function Impairment and in Healthy Subjects

Hepatic Impairment Clinical Trial

Official title:

To Evaluate the Pharmacokinetics and Safety of Yimitasvir Phosphate Capsules in Subjects With Moderate and Severe Liver Function Impairment and Healthy Subjects in a Single-center, Non-randomized, Open, Single-dose Administration

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04552808
• Other study ID #: PCD-DDAG181PA-18-004
• Status: Completed
• Phase: Phase 1
• Start date: October 19, 2020
• Est. completion date: June 9, 2022

Study information

• Verified date: October 2020
• Source: Sunshine Lake Pharma Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the pharmacokinetics and safety of Yimitasvir phosphate capsules in subjects with moderate and severe liver function impairment and healthy subjects in a single-center, non-randomized, open, single-dose administration

Description:

A phase I, a single-center, non-randomized, open, single-dose administration study to explore the safety, pharmacokinetics of Yimitasvir phosphate capsules in subjects with moderate and severe liver function impairment and healthy subjects This study is divided into four cohorts, cohort A and cohort C in healthy subjects, cohort B for moderate liver function impairment participants, cohort D for severe liver function impairment, participants in cohort A and cohort B, group C and group D should be matched in terms of sex, age, and body mass index (BMI). A total of 32 subjects, 8 in each cohort, both male and female, are planned to be enrolled. If a complete PK blood sample is not collected due to subjects' early withdrawal from the study, new subjects will be enrolled to meet the pharmacokinetic parameters that can be evaluated for each cohort of 8 subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: June 9, 2022
• Est. primary completion date: June 9, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Sign the informed consent form before the trial and fully understand the contents of the trial, the process and possible adverse reactions.

2. subjects and must be 18 to 70 years of age inclusive.

3. Subjects (including partners) have no pregnancy plan within 3 months after the last dose of study drug and voluntarily take effective contraceptive measures. The following inclusion criteria are only applicable to healthy subjects with normal liver

function (cohorts A and C) :

1. The gender and age (±5 years) of subjects in cohort A and C were paired with subjects in cohort B and D, respectively.

2. Body mass index (BMI) : 18-30 kg/m^2 (including critical value) [BMI= weight (kg)/height^2 (m^2)] (BMI matching ±15% with liver dysfunction cohort);

3. Physical examination and vital signs without clinically significant abnormalities. The following inclusion criteria are only applicable to subjects with liver dysfunction

(cohort B and D) :

1. Body mass index (BMI) between 18 and 28 kg/m^2 (including critical value) is allowed for subjects with liver insufficiency without ascites or subjects with subclinical ascites detected only by ultrasound or other imaging.Subjects with clinically significant ascites with liver dysfunction were allowed to have a BMI of 18~30 kg/m^2 (including a threshold).

2. During screening, the severity of patients with liver dysfunction was evaluated according to the Child-Pugh classification : (B/moderate: Child-Pugh score 7~9; Grade C/Severe: Child Pugh score 10~15 points).

3. The liver function status of the subjects was determined to be stable between 1 month before taking the experimental drug and the end of the study, with no significant change.

Exclusion Criteria:

1. Use of >5 cigarettes per day during the past 3 months.

2. Known history of allergy to study drugs,or allergies constitution ( multiple drug and food allergies).

3. History of alcohol abuse .

4. Donation or loss of blood over 400 mL within 3 months prior to screening. 5.12-lead ECG with clinically significant. The following exclusion criteria apply only to healthy subjects with normal liver function

(cohorts A and C) :

1. Hepatitis B surface antigen (HBsAg) was screened for positivity.

2. Have taken any drug (including prescription and non-prescription drugs, herbal preparations) within 2 weeks prior to taking the experimental drug. The following exclusion criteria apply only to subjects with liver function impairment

(cohorts B and D) :

1. ALT>10×ULN;

2. Absolute count of neutrophils <0.75×10^9/L;

3. PLT<50×10^9/L

4. HGB<60 g/L

5. AFP >100 ng/mL; If 20 ng/mL=AFP=100 ng/mL, liver ultrasound examination or other imaging examinations (CT, MRI, etc.) are required to exclude subjects with suspected HCC.

6. eGFR<60 mL/min/1.73m^2.

Related Conditions & MeSH terms

• Hepatic Impairment

Intervention

Drug:
• Yimitasvir Phosphate
Cohort A: On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects
• Yimitasvir Phosphate
Cohort B: were subjects with moderate liver function impairment. On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects.
• Yimitasvir Phosphate
Cohort C: Cohort C are healthy subjects, cohorts C and D, should be matched in terms of sex, age, and body mass index (BMI). On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects.
• Yimitasvir Phosphate
Cohort D: were subjects with severe liver function impairment. On the first day, 100 mg of Yimitasvir phosphate was given in a single dose on fasted by each subjects.

Locations

Country	Name	City	State
China	West China Hospital of Sichuan University	Chendu	Sichuan

Sponsors (1)

Lead Sponsor	Collaborator
Sunshine Lake Pharma Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse Events	Incidence of adverse events	From Days 1-7
Primary	Cmax	Maximum plasma concentration of study drugs	From Days 1-5
Primary	AUC	Maximum plasma concentration of study drugs	From Days 1-5